Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2020 Financial Results on Thursday, Mar...
March 03 2021 - 8:30AM
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset
clinical-stage biopharmaceutical company focused on identifying,
developing and commercializing treatments in high unmet need areas
involving multi-drug resistant bacterial infections and rare
diseases, today announced that it will host a conference call and
live audio webcast on March 11, 2021 at 4:30 p.m.
EST to report its fourth quarter and full-year 2020 financial
results and provide an update on its business and pipeline.
To access the call, please dial (877) 705-6003
(domestic) or (201) 493-6725 (international) and refer to
conference ID 13716494. The audio webcast can be accessed under
“Events and Presentations” in the Investor and Media section of the
Company’s website at www.sperotherapeutics.com. The archived
webcast will also be available on Spero’s website for 30 days
following the call.
About Spero TherapeuticsSpero
Therapeutics, Inc. is a multi-asset, clinical-stage
biopharmaceutical company focused on identifying, developing and
commercializing novel treatments for multi-drug-resistant (MDR)
bacterial infections and rare diseases.
Spero’s lead product candidate, tebipenem HBr
(tebipenem pivoxil hydrobromide; formerly SPR994), is being
developed as the first oral carbapenem antibiotic for use in
complicated urinary tract infections (cUTI) and acute
pyelonephritis (AP). In September 2020, Spero announced
positive top-line results from its Phase 3 ADAPT-PO clinical trial
of tebipenem HBr in cUTI and AP.
Spero is also developing SPR720, its novel oral
therapy product candidate being developed for the treatment of
rare, orphan pulmonary disease caused by non-tuberculous
mycobacterial (NTM) infections.
Spero also has an IV-administered next
generation polymyxin product candidate, SPR206, developed from its
potentiator platform that is being developed to treat MDR
Gram-negative infections in the hospital setting.
For more information,
visit https://sperotherapeutics.com.
Spero Investor and Media
Contact:Sharon KlahreVice President, Investor
Relations857-242-1547IR@sperotherapeutics.com
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Sep 2023 to Sep 2024